# Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)

> **NCT05435027** · PHASE1 · COMPLETED · sponsor: **Gritstone bio, Inc.** · enrollment: 342 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** GRT-R912, samRNA-Spikebeta-TCE11
- **DRUG:** GRT-R914, samRNA-Spikebeta-TCE9
- **DRUG:** GRT-R918, samRNA-SpikeOmicron-N-TCE11

## Key facts

- **NCT ID:** NCT05435027
- **Lead sponsor:** Gritstone bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-03-06
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435027, "Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05435027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*